Evidence map›Paper›PMID 40835978›Full record

ReviewNature reviews. Microbiology2026

Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment.

Joshua B Parsons, Ahmad Mourad, Brian P Conlon, Tammy Kielian, Vance G Fowler

Abstract readReview
In one paragraph

Review in Nature reviews. Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The evolving landscape ofFrontiers in immunology · 2026
    Pooled it
  2. Article
  3. Article
  4. Electronic Chip-Mimetic Medical Implants for Controllable Sonothermal Treatments.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Global Transcriptional Differences inAntibiotics (Basel, Switzerland) · 2026
    Article
  6. Article
  7. Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. ROS-Balancing MXene/MoSeSmall (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joshua B ParsonsDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Ahmad MouradDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0002-3149-597X
Brian P ConlonDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-2155-8375
Tammy KielianDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0001-7624-670X
Vance G FowlerDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA. vance.fowler@duke.edu.ORCID http://orcid.org/0000-0002-8048-0897

Funding

The S. aureus biofilm lifecycleP01AI083211 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KIELIAN, TAMMY L · 2009 to 2023
$32.1M
HLA Fine Mapping to Elucidate S. aureus SusceptibilityR01AI165671 · NIAID · DUKE UNIVERSITY · PI FOWLER, VANCE G., SCOTT, WILLIAM K · 2021 to 2025
$3.8M
T cell-innate immune crosstalk regulates Staphylococcus aureus craniotomy infectionR01AI169788 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Tammy L Kielian · 2022 to 2026
$2.9M
Diabetes and Antibiotic Treatment FailureR01AI173004 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian Patrick Conlon, Lance R. Thurlow · 2023 to 2026
$2.8M
Calprotectin and Antibiotic Activities at the Infection InterfaceR01AI179695 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian Patrick Conlon, Thomas Everett Kehl-Fie · 2024 to 2026
$2.3M
Microbial Genomic Determinants of Antibiotic Treatment Failure in Staphylococcus aureus BacteremiaK08AI187747 · NIAID · DUKE UNIVERSITY · PI Joshua B Parsons · 2025 to 2026
$380k
NIAID NIH HHS K08 AI187747NIAID NIH HHS P01 AI083211NIAID NIH HHS R01 AI165671NIAID NIH HHS R01 AI169788NIAID NIH HHS R01 AI173004NIAID NIH HHS R01 AI179695
6 · The paper itself

Abstract

Staphylococcus aureus is capable of infecting every organ system in the body and developing resistance to every available antibiotic used to treat it, such as methicillin-resistant S. aureus (commonly referred to as MRSA). This pathogen is characterized by the sudden emergence of virulent new clones and an array of mechanisms to circumvent the immune system and antibiotics. Furthermore, despite the development of new antibiotics and a growing body of high-quality data to inform their use, S. aureus continues to be a leading bacterial cause of death worldwide. In this Review, we provide an overview of the basic research on the complex interplay between S. aureus, the host and antibiotics. We also provide an update on the contemporary clinical studies on the treatment and prevention of S. aureus.

Indexed as

Anti-Bacterial AgentsImmune EvasionMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsStaphylococcus aureusAnimalsHost-Pathogen InteractionsHumansAnti-Bacterial Agents

Identifiers

PMID40835978
PMCPMC13617386

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.